SLC5A2 and atrial fibrillation: However, given the exploratory nature of the present analysis (and the post hoc analysis from the DECLARE‐TIMI 58 trial) as well as the lack of adjudication and systematic screening for new‐onset AF in both trials, the potential anti‐fibrillatory effect of SGLT2 inhibitors merits further investigation in a prospective manner, perhaps using systematic ECG monitoring which is likely to detect a higher incidence of new‐onset AF.